Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan

Hsu, Chih‐Wei; Lee, Sheng-Yu; Wang, Liang‐Jen

doi:10.1007/s00787-018-1242-9

Cited by 18 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The onset of mental disorders, including schizophrenia and other psychotic disorders, commonly occurs in adolescence due to important changes in the brain structure with complex interactions among biological, psychological and social factors [ 10 ]. Most of the antipsychotic users identified in this study with a diagnosis of schizophrenia were adolescents in the age range 13–17 years, consistent with other studies from Canada, Taiwan, and Denmark [ 7 , 8 , 22 ].…”

Section: Discussionsupporting

confidence: 90%

“…The high prescription rate of risperidone followed by olanzapine for the treatment of children and adolescents with schizophrenia has been confirmed in other studies [ 7 , 17 , 30 ]. This can be attributed to the increase in the diagnosis of schizophrenia and other mental disorders in this age group, the implementation of diagnostic criteria for schizophrenia, improved access to intervention services and an increase in treatment capacity [ 4 , 8 ].…”

Section: Discussionsupporting

confidence: 57%

“…Oestrogen seems to be psychoprotective and to influence the development and functioning of the brain in females, whereas hypothalamic–pituitary–gonadal dysfunction can influence both sexes [ 27 ]. On the other hand, some recent studies argue that the usual male predominance found in schizophrenia has become less apparent or that there is no gender difference [ 4 , 7 , 8 ]. Evidence regarding the gender difference in the risk of schizophrenia is still inconclusive [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…Male schizophrenia patients tend to show an earlier age of onset, more negative symptoms, higher relapse rate, poor outcomes and worse responses to antipsychotics than female schizophrenic patients [ 6 ]. Other studies have not endorsed the gender difference and showed controversial results or no significant differences between males and females [ 4 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

2021

View full text Add to dashboard Cite

Background The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes. The aim of this study was to investigate gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil. Methods We conducted a cross-sectional study of outpatients with EOS aged 10 to 17 years who received at least one provision of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine or ziprasidone) from a large Brazilian pharmaceutical assistance programme. Data were retrieved from a nationwide administrative database from 2008 to 2017. Results Of the 49,943 patients with EOS, 63.5% were males, and the mean age was 13.6 years old. The patients were using risperidone (62.5%), olanzapine (19.6%), quetiapine (12.4%), ziprasidone (3.3%) and clozapine (2.2%). We found gender differences, especially in the 13–17 year age group (65.1% for males vs. 34.9% for females, p < 0.001), in the use of risperidone (72.1% for males vs. 27.9% for females, p < 0.001) and olanzapine (66.5% for males vs. 33.5% for females, p < 0.001). Only in the 13 to 17 years age group were the prescribed doses of olanzapine (p = 0.012) and quetiapine (p = 0.041) slightly higher for males than for females. Conclusions Our findings showed gender differences among patients diagnosed with EOS and who received atypical antipsychotics. More attention should be devoted to gender differences in research and clinical practice.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

2021

View full text Add to dashboard Cite

show abstract

“…There have been many investigations into gender differences in schizophrenia. Men are reported to show more premorbid difficulties, but the overall prevalence of schizophrenia symptoms is similar in the two sexes [ 5 ]. With respect to comorbidity, men and women are vulnerable to somewhat different health problems [ 6 ].…”

Section: Introduction: Health Care For Women With Schizophreniamentioning

confidence: 99%

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

González-Rodríguez

Guàrdia²,

Pedrero

et al. 2020

IJERPH

View full text Add to dashboard Cite

Women with schizophrenia show sex-specific health needs that differ according to stage of life. The aim of this narrative review is to resolve important questions concerning the treatment of women with schizophrenia at different periods of their life—paying special attention to reproductive and post-reproductive stages. Review results suggest that menstrual cycle-dependent treatments may be a useful option for many women and that recommendations re contraceptive options need always to be part of care provision. The pregnancy and the postpartum periods—while constituting vulnerable time periods for the mother—require special attention to antipsychotic effects on the fetus and neonate. Menopause and aging are further vulnerable times, with extra challenges posed by associated health risks. Pregnancy complications, neurodevelopmental difficulties of offspring, cancer risk and cognitive defects are indirect results of the interplay of hormones and antipsychotic treatment of women over the course of the lifespan. The literature recommends that health promotion strategies need to be directed at lifestyle modifications, prevention of medical comorbidities and increased psychosocial support. Careful monitoring of pharmacological treatment has been shown to be critical during periods of hormonal transition. Not only does treatment of women with schizophrenia often need to be different than that of their male peers, but it also needs to vary over the course of life.

show abstract

Human-Induced Pluripotent Stem Cell–Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases

Kiris

2021

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Gender differences in the prevalence, comorbidities and antipsychotic prescription of early-onset schizophrenia: a nationwide population-based study in Taiwan

Cited by 18 publications

References 49 publications

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

Women with Schizophrenia over the Life Span: Health Promotion, Treatment and Outcomes

Human-Induced Pluripotent Stem Cell–Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases

Contact Info

Product

Resources

About